Orchid Pharma Quarterly Results
Orchid Pharma quarterly results. In Mar 2026, Orchid Pharma (ORCHPHARMA) reported revenue ₹376 Cr and net profit ₹26 Cr — revenue +56.0% YoY. Check Orchid Pharma networth to track the company's total market size over time.
ORCHPHARMA Quarterly Results — Revenue, Profit & EPS Highlights
Orchid Pharma latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit Orchid Pharma stock price NSE.
- Revenue of ₹376 Cr in Mar 2026 (+22.9% vs Jun 2026, +56.0% vs Mar 2025)
- Net Profit of ₹26 Cr in Mar 2026 (+766.7% vs Jun 2026, +18.2% vs Mar 2025)
- EBITDA of ₹38 Cr in Mar 2026 (+137.5% vs Jun 2026)
- Operating Margin of 8.0% in Mar 2026 (+3.0pp vs Jun 2026)
- Earnings Per Share of ₹4.31 in Mar 2026 (+698.1% vs Jun 2026)
Orchid Pharma Quarterly Results — Revenue, EBITDA, Net Profit & EPS
ORCHPHARMA quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 376 | 306 | 204 | 241 | 275 | 22.9% | 56.0% |
| Net Profit (₹ Cr) | 26 | 3 | -6 | 22 | -6 | - | - |
| EBITDA (₹ Cr) | 38 | 16 | 9 | 32 | 6 | - | - |
| EPS (₹) | 4.31 | 0.54 | -1.13 | 4.40 | -0.95 | - | - |
| Operating Margin (%) | 8.0% | 5.0% | -1.0% | 12.0% | -2.0% | - | - |
ORCHPHARMA Share Price Trend — 1-Year Movement Across Quarterly Results
Orchid Pharma 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Review ORCHPHARMA P/E ratio to evaluate earnings-based valuation against sector peers.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
ORCHPHARMA vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Orchid Pharma latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹432,120.23 Cr | 1779.7 | 15,018 | 2,710 | -5.6% | - | 18.0% | 157.5 |
|
Divis Laboratories
Mar 2026 |
₹253,522.49 Cr | 9196.0 | 2,986 | 751 | -5.0% | - | 25.2% | 324.8 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4772.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 414.6 |
|
Zydus Life Science
Mar 2026 |
₹113,615.69 Cr | 1139.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 90.0 |
|
Cipla
Mar 2026 |
₹108,576.18 Cr | 1335.5 | 6,612 | 543 | -9.3% | - | 8.2% | 194.4 |
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores